Clinical Trial Update: Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated sirolimus (Rapamune) for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: University of Zurich | Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 3 | Status: COMPLETED